Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

Trial Details

NCT ID

NCT03271632

Phase

PHASE1 / PHASE2

Sponsor

Shenzhen Geno-Immune Medical Institute

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

CAR T cells

Locations (sample)

Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

Male and female subjects with surface antigen confirmed multiple myeloma with no available curative treatment options (including autologous or allo…
Complete remission (CR) cannot be achieved after at least 4 prior combination therapy regimens.
MM in CR2 or CR3 and not eligible for allogeneic SCT because of age, comorbid diseases, or lack of available donor.
Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval \< 1 year).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →